Common Contracts
9 similar Letter Agreement contracts by Arcadia Biosciences, Inc., BIT Mining LTD, Oncternal Therapeutics, Inc., others
BIT Mining Limited Units 813&815, Level 8, Core F, Cyberport 3Letter Agreement • August 18th, 2022 • BIT Mining LTD • Services-computer processing & data preparation • New York
STRICTLY CONFIDENTIAL Arcadia Biosciences, Inc.Letter Agreement • August 16th, 2022 • Arcadia Biosciences, Inc. • Agricultural production-crops • New York
BIT Mining Limited Units 813&815, Level 8, Core F, Cyberport 3Letter Agreement • June 27th, 2022 • BIT Mining LTD • Services-computer processing & data preparation • New York
STRICTLY CONFIDENTIAL Kintara Therapeutics, Inc. 12707 High Bluff Dr., Suite 200 San Diego, CA 92130 Attn: Saiid Zarrabian, Chief Executive Officer Dear Mr. Zarrabian:Letter Agreement • September 28th, 2021 • Kintara Therapeutics, Inc. • Pharmaceutical preparations • New York
This letter agreement (this “Agreement”) constitutes the agreement between Kintara Therapeutics, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclusive agent, advisor or underwriter in any offering (each, an “Offering”) of securities of the Company (the “Securities”) during the Term (as hereinafter defined) of this Agreement. The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright’s assistance in an Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwrig
STRICTLY CONFIDENTIAL Oncternal Therapeutics, Inc. 12230 El Camino Real Suite 300 San Diego, California 92130 Attn: James B. Breitmeyer, M.D., Ph.D., President and Chief Executive OfficerLetter Agreement • March 12th, 2021 • Oncternal Therapeutics, Inc. • Pharmaceutical preparations • New York
This letter agreement (this “Agreement”) constitutes the agreement between Oncternal Therapeutics, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclusive agent, advisor or underwriter in any offering (each, an “Offering”) of securities of the Company (the “Securities”) during the Term (as hereinafter defined) of this Agreement. The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright’s assistance in an Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwr
STRICTLY CONFIDENTIAL Oncternal Therapeutics, Inc. 12230 El Camino Real Suite 300 San Diego, California 92130 Attn: James B. Breitmeyer, M.D., Ph.D., President and Chief Executive OfficerLetter Agreement • March 11th, 2021 • Oncternal Therapeutics, Inc. • Pharmaceutical preparations • New York
This letter agreement (this “Agreement”) constitutes the agreement between Oncternal Therapeutics, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclusive agent, advisor or underwriter in any offering (each, an “Offering”) of securities of the Company (the “Securities”) during the Term (as hereinafter defined) of this Agreement. The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright’s assistance in an Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwr
STRICTLY CONFIDENTIAL Arcadia Biosciences, Inc.Letter Agreement • December 22nd, 2020 • Arcadia Biosciences, Inc. • Agricultural production-crops • New York
STRICTLY CONFIDENTIAL China Jo-Jo Drugstores, Inc. Hai Wai Hai Tongxin Mansion Floor 6 Gong Shu District, Hangzhou City People’s Republic of China 310008 Attn: Lei Liu, Chief Executive OfficerLetter Agreement • June 2nd, 2020 • China Jo-Jo Drugstores, Inc. • Retail-drug stores and proprietary stores • New York
This letter agreement (this “Agreement”) constitutes the agreement between China Jo-Jo Drugstores, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclusive agent, advisor or underwriter in any offering of securities of the Company (the “Securities”) during the Term (as hereinafter defined) of this Agreement (each, an “Offering”). The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright’s assistance in an Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwr
STRICTLY CONFIDENTIAL Aeterna Zentaris Inc.Letter Agreement • February 21st, 2020 • Aeterna Zentaris Inc. • Pharmaceutical preparations • New York
